Head of Infectious Disease for Translational Medicine
Pfizer Inc
Mary Lynn Baniecki has a PhD in Molecular and Cellular Pharmacology and is the Head of Infectious Disease for Translational Medicine in Early Clinical Development at Pfizer. She is the translational lead for the development of PAXLOVID. Mary Lynn has more than 15 years of experience leading translational biomarker and diagnostics strategies to enable precision medicine across a multitude of diseases including metabolic, autoimmune, and infectious (viral and parasitic) diseases. Prior to joining Pfizer, Mary Lynn was a Scientist in the department of microbial and infectious disease at the Broad Institute of MIT and Harvard. As a precision medicine subject matter expert, Mary Lynn has been recognized by multiple internal awards and external speaking engagements.